Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
01 May 2024
01 May 2024
Historique:
received:
13
06
2023
accepted:
17
04
2024
medline:
2
5
2024
pubmed:
2
5
2024
entrez:
1
5
2024
Statut:
epublish
Résumé
Cerebrospinal fluid (CSF) biomarkers reflect brain pathophysiology and are used extensively in translational research as well as in clinical practice for diagnosis of neurological diseases, e.g., Alzheimer's disease (AD). However, CSF biomarker concentrations may be influenced by non-disease related inter-individual variability. Here we use a data-driven approach to demonstrate the existence of inter-individual variability in mean standardized CSF protein levels. We show that these non-disease related differences cause many commonly reported CSF biomarkers to be highly correlated, thereby producing misleading results if not accounted for. To adjust for this inter-individual variability, we identified and evaluated high-performing reference proteins which improved the diagnostic accuracy of key CSF AD biomarkers. Our reference protein method attenuates the risk for false positive findings, and improves the sensitivity and specificity of CSF biomarkers, with broad implications for both research and clinical practice.
Identifiants
pubmed: 38693142
doi: 10.1038/s41467-024-47971-5
pii: 10.1038/s41467-024-47971-5
doi:
Substances chimiques
Biomarkers
0
Cerebrospinal Fluid Proteins
0
Amyloid beta-Peptides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
3676Informations de copyright
© 2024. The Author(s).
Références
Nichols, E. et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 7, e105–e125 (2022).
doi: 10.1016/S2468-2667(21)00249-8
Hansson, O. Biomarkers for neurodegenerative diseases. Nat. Med 27, 954–963 (2021).
pubmed: 34083813
doi: 10.1038/s41591-021-01382-x
Zetterberg, H. & Blennow, K. Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics. Mol. Neurodegener. 16, 10 (2021).
pubmed: 33608044
pmcid: 7893769
doi: 10.1186/s13024-021-00430-x
Scheltens, P. et al. Alzheimer’s disease. Lancet 388, 505–517 (2016).
pubmed: 26921134
doi: 10.1016/S0140-6736(15)01124-1
van Dyck, C. H. et al. Lecanemab in Early Alzheimer’s Disease. N. Engl. J. Med. 388, 9–21 (2023).
pubmed: 36449413
doi: 10.1056/NEJMoa2212948
Mintun, M. A. et al. Donanemab in Early Alzheimer’s Disease. N. Engl. J. Med. 384, 1691–1704 (2021).
pubmed: 33720637
doi: 10.1056/NEJMoa2100708
Mallinckrodt, C. et al. Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab. J. Prevent. Alzheimer’s Dis. https://doi.org/10.14283/jpad.2023.6 (2023).
Sakka, L., Coll, G. & Chazal, J. Anatomy and physiology of cerebrospinal fluid. Eur. Ann. Otorhinolaryngol. Head. Neck Dis. 128, 309–316 (2011).
pubmed: 22100360
doi: 10.1016/j.anorl.2011.03.002
Spector, R., Robert Snodgrass, S. & Johanson, C. E. A balanced view of the cerebrospinal fluid composition and functions: focus on adult humans. Exp. Neurol. 273, 57–68 (2015).
pubmed: 26247808
doi: 10.1016/j.expneurol.2015.07.027
Johanson, C. E. et al. Multiplicity of cerebrospinal fluid functions: New challenges in health and disease. Cerebrospinal Fluid Res. 5, 10 (2008).
Tumani, H., Huss, A. & Bachhuber, F. The cerebrospinal fluid and barriers – anatomic and physiologic considerations. in Handbook of Clinical Neurology vol. 146 3–20 (Elsevier B.V., 2017).
Bouwman, F. H. et al. Clinical application of CSF biomarkers for Alzheimer’s disease: from rationale to ratios. Alzheimer’s Dement.: Diagnosis, Assess. Dis. Monit. 14, e12314 (2022).
Guo, T. et al. Normalization of CSF pTau measurement by Aβ40improves its performance as a biomarker of Alzheimer’s disease. Alzheimers Res. Ther. 12, 97 (2020).
pubmed: 32799929
pmcid: 7429887
doi: 10.1186/s13195-020-00665-8
Hansson, O. et al. The genetic regulation of protein expression in cerebrospinal fluid. EMBO Mol. Med. 15, e16359 (2023).
Jantos-Siwy, J. et al. Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J. Proteome Res. 8, 268–281 (2009).
pubmed: 19012428
doi: 10.1021/pr800401m
Eric Thomas, C., Sexton, W., Benson, K., Sutphen, R. & Koomen, J. Urine collection and processing for protein biomarker discovery and quantification. Cancer Epidemiol. Biomark. Prev. 19, 953–959 (2010).
doi: 10.1158/1055-9965.EPI-10-0069
Jack, C. R. et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s Dement. 14, 535–562 (2018).
doi: 10.1016/j.jalz.2018.02.018
Bäckström, D. et al. NfL as a biomarker for neurodegeneration and survival in Parkinson disease. Neurology 95, E827–E838 (2020).
pubmed: 32680941
pmcid: 7605503
doi: 10.1212/WNL.0000000000010084
Düzel, E. et al. Amyloid pathology but not APOE ϵ4 status is permissive for tau-related hippocampal dysfunction. Brain 145, 1473–1485 (2022).
pubmed: 35352105
pmcid: 9128811
doi: 10.1093/brain/awab405
Suárez-Calvet, M. et al. Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology. Mol. Neurodegener. 14, 1 (2019).
Brosseron, F. et al. Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer’s disease. Neuron 110, 1009–1022.e4 (2022).
pubmed: 34995486
doi: 10.1016/j.neuron.2021.12.016
Delmotte, K., Schaeverbeke, J., Poesen, K. & Vandenberghe, R. Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer’s disease. Alzheimers Res. Ther. 13, 84 (2021).
pubmed: 33879243
pmcid: 8059197
doi: 10.1186/s13195-021-00817-4
Nordengen, K. et al. Glial activation and inflammation along the Alzheimer’s disease continuum. J. Neuroinflamm. 16, 46 (2019).
doi: 10.1186/s12974-019-1399-2
Ou, Y. N. et al. FDG-PET as an independent biomarker for Alzheimer’s biological diagnosis: A longitudinal study. Alzheimers Res. Ther. 11, 57 (2019).
Soldan, A. et al. ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. Neurology 92, E1567–E1579 (2019).
pubmed: 30842300
pmcid: 6448449
doi: 10.1212/WNL.0000000000007248
Pouclet-Courtemanche, H. et al. Frontotemporal dementia is the leading cause of “true” A−/T+ profiles defined with Aβ 42/40 ratio. Alzheimer’s Dement. Diagnosis, Assess. Dis. Monit. 11, 161–169 (2019).
Oberstein, T. J. et al. Amyloid-β levels and cognitive trajectories in non-demented pTau181-positive subjects without amyloidopathy. Brain 145, 4032–4041 (2022).
pubmed: 35973034
pmcid: 9679169
doi: 10.1093/brain/awac297
Yoon, B. et al. Abnormal tau in amyloid PET negative individuals. Neurobiol. Aging 109, 125–134 (2022).
pubmed: 34715443
doi: 10.1016/j.neurobiolaging.2021.09.019
Majbour, N. K. et al. Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease. Sci. Rep. 7, 40263 (2017).
pubmed: 28071698
pmcid: 5223278
doi: 10.1038/srep40263
Janelidze, S. et al. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology 91, e867–e877 (2018).
pubmed: 30054439
pmcid: 6133624
doi: 10.1212/WNL.0000000000006082
Janelidze, S. et al. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer’s disease. Ann. Clin. Transl. Neurol. 3, 12–20 (2016).
pubmed: 26783546
doi: 10.1002/acn3.266
Tijms, B. M. et al. Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomics. Brain 143, 3776–3792 (2020).
pubmed: 33439986
pmcid: 7805814
doi: 10.1093/brain/awaa325
Janelidze, S. et al. CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: Better diagnostic markers of Alzheimer disease. Ann. Clin. Transl. Neurol. 3, 154–165 (2016).
pubmed: 27042676
pmcid: 4774260
doi: 10.1002/acn3.274
Hansson, O., Lehmann, S., Otto, M., Zetterberg, H. & Lewczuk, P. Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease. Alzheimers Res Ther. 11, 1–15 (2019).
doi: 10.1186/s13195-019-0485-0
Zetterberg, H., Blennow, K. & Hanse, E. Amyloid β and APP as biomarkers for Alzheimer’s disease. Exp. Gerontol. 45, 23–29 (2010).
pubmed: 19698775
doi: 10.1016/j.exger.2009.08.002
van der Maaten, L. & Hinton, G. Visualizing Data Using T-SNE. J. Mach. Learn. Res. 9, 2579–2605 (2008).
Hartigan, J. A. Clustering Algorithms. (Wiley, New York, 1975).
Pichet Binette, A. et al. Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease. Nat. Commun. 13, 6635 (2022).
pubmed: 36333294
pmcid: 9636262
doi: 10.1038/s41467-022-34129-4
Jansen, I. E. et al. Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers. Acta Neuropathol. 144, 821–842 (2022).
pubmed: 36066633
pmcid: 9547780
doi: 10.1007/s00401-022-02454-z
May, C. et al. Cerebrospinal fluid production is reduced in healthy aging. Neurology 40, 500 (1990).
pubmed: 2314595
doi: 10.1212/WNL.40.3_Part_1.500
Fleischman, D. et al. Cerebrospinal fluid pressure decreases with older age. PLoS One 7, e52664 (2012).
pubmed: 23300737
pmcid: 3530461
doi: 10.1371/journal.pone.0052664
Liu, G. et al. Direct measurement of cerebrospinal fluid production in mice. Cell Rep. 33, 108524 (2020).
pubmed: 33357428
pmcid: 8186543
doi: 10.1016/j.celrep.2020.108524
Preston, J. E. Ageing choroid plexus-cerebrospinal fluid system. Microsc. Res. Tech. 52, 31–37 (2001).
pubmed: 11135446
doi: 10.1002/1097-0029(20010101)52:1<31::AID-JEMT5>3.0.CO;2-T
Nakajima, M. et al. Guidelines for management of idiopathic normal pressure hydrocephalus (Third edition): endorsed by the Japanese society of normal pressure hydrocephalus. Neurol. Med. Chir. 61, 63–97 (2021).
doi: 10.2176/nmc.st.2020-0292
Liu, G., Ladrón-de-Guevara, A., Izhiman, Y., Nedergaard, M. & Du, T. Measurements of cerebrospinal fluid production: a review of the limitations and advantages of current methodologies. Fluids Barriers CNS 19, 101 (2022).
Ossenkoppele, R. et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat. Med. 28, 2381–2387 (2022).
pubmed: 36357681
pmcid: 9671808
doi: 10.1038/s41591-022-02049-x
Tan, M. S. et al. Longitudinal trajectories of Alzheimer’s ATN biomarkers in elderly persons without dementia. Alzheimers Res. Ther. 12, 55 (2020).
Allegri, R. F. et al. Prognostic value of ATN Alzheimer biomarkers: 60-month follow-up results from the Argentine Alzheimer’s Disease Neuroimaging Initiative. Alzheimer’s and Dementia: Diagnosis, Assessment and Disease Monitoring 12, e12026 (2020).
Delvenne, A. et al. Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer’s disease pathophysiology. Alzheimer’s Dement. https://doi.org/10.1002/alz.12713 (2022).
Palmqvist, S. et al. Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures. Nat. Med. (2021) https://doi.org/10.1038/s41591-021-01348-z .
Palmqvist, S. et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. J. Am. Med. Assoc. 324, 772–781 (2020).
doi: 10.1001/jama.2020.12134
Palmqvist, S. et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer’s disease. EMBO Mol. Med. 11, e11170 (2019).
Palmqvist, S. et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-Amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. 71, 1282–1289 (2014).
pubmed: 25155658
doi: 10.1001/jamaneurol.2014.1358
Salvadó, G. et al. Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: a multi-cohort study. Alzheimer’s Dement. https://doi.org/10.1002/alz.12907 (2023).
Amadoru, S. et al. Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease. Alzheimers Res. Ther. 12, 22 (2020).
Cho, H. et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann. Neurol. 80, 247–258 (2016).
pubmed: 27323247
doi: 10.1002/ana.24711
Leuzy, A. et al. Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of alzheimer disease from other neurodegenerative disorders. JAMA Neurol. 77, 955–965 (2020).
pubmed: 32391858
doi: 10.1001/jamaneurol.2020.0989
Liao, Y., Wang, J., Jaehnig, E. J., Shi, Z. & Zhang, B. WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res. 47, W199–W205 (2019).
pubmed: 31114916
pmcid: 6602449
doi: 10.1093/nar/gkz401
Dataset: Allen Institute for Brain Science (2022). Allen Cell Types Database – Human MTG 10x [dataset]. Available from celltypes.brain-map.org/rnaseq .
Harris, C. R. et al. Array programming with NumPy. Nature 585, 357–362 (2020).
pubmed: 32939066
pmcid: 7759461
doi: 10.1038/s41586-020-2649-2
Mckinney, W. Data Structures for Statistical Computing in Python. Proceedings of the 9th Python in Science Conference, 56–61 https://doi.org/10.25080/Majora-92bf1922-00a (2010).
Hunter J. Matplotlib: A 2D graphics environment. Comput. Sci. Eng. 9, 90–95 (2007).
Pedregosa, F. et al. Scikit-Learn: Machine Learning in Python. J. Mach. Learn. Res. 12 http://scikit-learn.sourceforge.net . (2011).
Seabold, S. & Perktold, J. Statsmodels: Econometric and Statistical Modeling with Python. Proceedings of the 9th Python in Science Conference (2010).
Vallat, R. Pingouin: statistics in Python. J. Open Sour. Softw. 3, 1026 (2018).
doi: 10.21105/joss.01026
Wickham, H. et al. Welcome to the Tidyverse. J. Open Sour. Softw. 4, 1686 (2019).
doi: 10.21105/joss.01686
Robin, X. et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinform. 12, (2011).